Positive results for Moderna.
After conducting clinical trials on thousands of people, the US biotech company said its vaccine was 93% effective six months after the second dose was injected.
In a press release published on the occasion of its second quarter results, Moderna also ensures that the booster doses currently tested against the variants show "robust" results.
“But we recognize that the Delta variant is an important new threat, so we must remain vigilant,” said his boss Stéphane Bancel, however.
The recall still in the testing phase
The company is testing several versions of a booster dose to increase immune protection against variants: a third dose of the initial vaccine, a new formula based on the Beta variant (first identified in South Africa), and a dose containing in equal parts the initial vaccine and the new formula.
The three different candidates “triggered robust antibody production” against the Delta variant, as well as against the Gamma and Beta variants, Moderna said.
The results of these phase 2 trials have been submitted for publication in a scientific journal, she said.
The company, which has applied for full authorization for its vaccine in the United States, also said it expected to have provided in August all the information necessary to obtain it.
Covid-19: Brussels announces an early purchase contract for vaccines with Novavax
Coronavirus: Full US green light for Pfizer vaccine set to arrive in September